Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Decision to self-isolate during the COVID-19 pandemic in the UK: a rapid scoping review

Keene CM. et al, (2024), BMJ Open, 14, e084437 - e084437

Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.

van Heerden JK. et al, (2024), Journal of acquired immune deficiency syndromes (1999), 95, 260 - 267

Supporting re-engagement with HIV services after treatment interruption in South Africa: a mixed method program evaluation of MSF's Welcome Service.

Arendse KD. et al, (2024), Scientific reports, 14

Between empathy and anger: healthcare workers’ perspectives on patient disengagement from antiretroviral treatment in Khayelitsha, South Africa - a qualitative study

Nhemachena T. et al, (2023), BMC Primary Care, 24

Conceptualising engagement with HIV care for people on treatment: the Indicators of HIV Care and AntiRetroviral Engagement (InCARE) Framework

Keene CM. et al, (2023), BMC Health Services Research, 23

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.

Griesel R. et al, (2023), The lancet. HIV

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks.

Keene CM. et al, (2023), J Acquir Immune Defic Syndr

Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a non-comparative, double-blind, randomised placebo-controlled trial.

Zhao Y. et al, (2023), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Synthetic auxin herbicides do not injure intermediate wheatgrass or affect grain yield

Shoenberger ED. et al, (2023), Weed Technology

Include forthcoming?